Start for free
Start for free
Droia Ventures logo

Droia Ventures

Europe, Luxembourg, Luxembourg, Luxembourg

Description

Droia is a specialist investor, exclusively focused on the development of oncology and genetic disease therapies.

Investor Profile

Droia Ventures has made 33 investments, with 4 in the past 12 months and 33% as lead.

Stage Focus

  • Series A (39%)
  • Series B (24%)
  • Series C (18%)
  • Seed (12%)
  • Series Unknown (6%)

Country Focus

  • United States (70%)
  • The Netherlands (15%)
  • Belgium (9%)
  • Singapore (3%)
  • Denmark (3%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Health Care
  • Biopharma
  • Life Science
  • Precision Medicine
  • Genetics
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Droia Ventures frequently co-invest with?

EcoR1 Capital
EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 4
The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research
North America, New York, United States, New York
Co-Investments: 4
Google Ventures
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 6
Celgene
Celgene
North America, New Jersey, United States, Summit
Co-Investments: 4
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 6
Novo Holdings
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 5
Pureos Bioventures
Pureos Bioventures
Europe, Zurich, Switzerland, Küsnacht
Co-Investments: 4
Polaris Partners
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 11
The Column Group
The Column Group
North America, California, United States, San Francisco
Co-Investments: 4
AbbVie Biotech Ventures
AbbVie Biotech Ventures
North America, Illinois, United States, North Chicago
Co-Investments: 4

What are some of recent deals done by Droia Ventures?

Hillstar Bio

Boston, Massachusetts, United States

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

BiotechnologyHealth CareMedical
Series AMar 25, 2025
Amount Raised: $67,000,000
Alesta Therapeutics

Leiden, Zuid-Holland, The Netherlands

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology
Series AJan 8, 2025
Amount Raised: $67,301,858
Judo Bio

Cambridge, Massachusetts, United States

Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.

BiotechnologyLife ScienceMedicalTherapeutics
Series AOct 7, 2024
Amount Raised: $75,000,000
Vico Therapeutics

Leiden, Zuid-Holland, The Netherlands

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health CareMedicalPharmaceutical
Series BJun 24, 2024
Amount Raised: $12,298,137
Frontier Medicines

San Francisco, California, United States

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

BiopharmaBiotechnologyLife SciencePharmaceuticalPrecision Medicine
Series CFeb 22, 2024
Amount Raised: $80,000,000
Accent Therapeutics

Lexington, Massachusetts, United States

Accent Therapeutics is a biopharmaceutical company.

BiotechnologyMedicalPharmaceuticalTherapeutics
Series CJan 23, 2024
Amount Raised: $75,000,000
Vico Therapeutics

Leiden, Zuid-Holland, The Netherlands

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health CareMedicalPharmaceutical
Series BJan 5, 2024
Amount Raised: $72,081,941
Hyku

Lexington, Massachusetts, United States

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.

BiopharmaBiotechnologyLife Science
SeedSep 19, 2023
Amount Raised: $56,000,000
Actio Biosciences

San Diego, California, United States

Actio Biosciences is a research center that develops drugs for rare diseases.

BioinformaticsBiotechnologyGenetics
Series ASep 12, 2023
Amount Raised: $55,000,000
QurAlis

Cambridge, Massachusetts, United States

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

BiotechnologyGeneticsHealth CarePrecision MedicineTherapeutics
Series BMar 9, 2023
Amount Raised: $88,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator